Avanir Pharmaceuticals announced that the FDA would likely delay receipt of its marketing application for Neurodex as its researchers respond to the agency's request to expand data analyses. The drug is being developed to help people with Alzheimer's and Lou Gehrig's disease manage uncontrollable laughter and crying. Avanir's stock dipped slightly on the news.
- read this AP story for more